Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 09, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
June 17, 2025 06:00 ET | Source: Immuneering Corporation

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
June 16, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
May 29, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering to Present at the Jefferies Global Healthcare Conference
May 05, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
April 02, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
March 21, 2025 16:30 ET | Source: Immuneering Corporation

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Corporation Announces Grant of Inducement Award
March 20, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 20, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

IMMUNEERING NAMES DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER
February 06, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Next Page keyboard_arrow_right